Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted therapies for cancer, will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 11-12, 2026. Brian Sullivan, the company’s CEO and co-founder, is slated to engage in a fireside chat on February 11 at 9:30 a.m. ET. Those interested can watch the live webcast through a designated link or via the Investors section of Celcuity’s official website, where a replay will also be made available shortly after.

Celcuity is advancing its lead therapeutic candidate, gedatolisib, a potent inhibitor targeting the PI3K/AKT/mTOR pathway—key in various solid tumors. This innovative therapy sets itself apart by blocking the pathway comprehensively, unlike other therapies that focus on single targets. Currently, Celcuity's clinical pipeline includes several significant trials. The Phase 3 VIKTORIA-1 trial is exploring gedatolisib in combination with fulvestrant, with enrollment completed for PIK3CA wild-type patients, while also enrolling the PIK3CA mutant cohort. Additionally, the Phase 3 VIKTORIA-2 trial is investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant for patients with HR+/HER2- advanced breast cancer, which is actively enrolling participants. The Phase 1/2 trial CELC-G-201 is also underway, focusing on patients with metastatic castration-resistant prostate cancer.

Celcuity is headquartered in Minneapolis, and further details about its ongoing clinical trials can be accessed on ClinicalTrials.gov. For more information about the company and its innovative therapies, visit Celcuity's website or connect on LinkedIn and X.

As Celcuity Inc. (Nasdaq: CELC) prepares to present at the Guggenheim Emerging Outlook: Biotech Summit 2026, there are several key factors for investors to consider regarding the company’s strategic direction and market potential.

Celcuity's proprietary lead candidate, gedatolisib, is a pan-PI3K and mTORC1/2 inhibitor, addressing the critical PI3K/AKT/mTOR pathway implicated in various cancers. The uniqueness of gedatolisib lies in its ability to simultaneously target multiple pathways, potentially offering differentiated efficacy compared to other therapies limited to targeting PI3K or mTOR alone. This mechanism positions Celcuity favorably in the intense oncology market.

As of early 2026, the company has completed enrollment in its Phase 3 VIKTORIA-1 clinical trial, which evaluates gedatolisib in patients with hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- ABC). Investors should closely monitor upcoming results from this trial, as positive outcomes could significantly bolster the stock's valuation. The ongoing VIKTORIA-2 trial further demonstrates Celcuity's commitment to expanding its clinical footprint, with the inclusion of a CDK4/6 inhibitor combining with gedatolisib, highlighting the potential for enhanced treatment options in first-line therapy scenarios.

Celcuity's presence at the Guggenheim summit provides a vital platform for management to articulate the company’s future direction and engage with potential investors. Market reactions may hinge on the clarity and enthusiasm of the messaging around upcoming trial data. Consequently, investors should watch for updates post-event, particularly with regard to trial timelines and potential partnerships, as these could greatly influence the company’s trajectory.

Given the highly speculative nature of biotech investments, stakeholders should approach Celcuity with a balanced view—recognizing both the high potential rewards from successful trial outcomes and the inherent risks involved in clinical-stage developments.